ProfileGDS4814 / ILMN_1751020
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 71% 72% 68% 69% 71% 67% 68% 70% 67% 72% 70% 71% 67% 67% 69% 67% 69% 70% 75% 72% 70% 70% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)75.943371
GSM780708Untreated after 4 days (C2_1)82.935172
GSM780709Untreated after 4 days (C3_1)65.935868
GSM780719Untreated after 4 days (C1_2)71.466769
GSM780720Untreated after 4 days (C2_2)78.84371
GSM780721Untreated after 4 days (C3_2)65.832767
GSM780710Trastuzumab treated after 4 days (T1_1)66.944468
GSM780711Trastuzumab treated after 4 days (T2_1)74.646270
GSM780712Trastuzumab treated after 4 days (T3_1)65.08167
GSM780722Trastuzumab treated after 4 days (T1_2)79.384472
GSM780723Trastuzumab treated after 4 days (T2_2)72.424770
GSM780724Trastuzumab treated after 4 days (T3_2)76.741771
GSM780713Pertuzumab treated after 4 days (P1_1)65.411367
GSM780714Pertuzumab treated after 4 days (P2_1)65.688867
GSM780715Pertuzumab treated after 4 days (P3_1)68.585469
GSM780725Pertuzumab treated after 4 days (P1_2)64.409167
GSM780726Pertuzumab treated after 4 days (P2_2)68.671169
GSM780727Pertuzumab treated after 4 days (P3_2)72.584770
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)96.666675
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)83.258372
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)72.220370
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)73.765870
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)71.079669